A NON-INTERVENTIONAL STUDY TO EVALUATE THE EFFECTIVENESS, SAFETY AND NURSE MANAGEMENT DURING INDUCTION TREATMENT WITH MABTHERA S.C. FOLLOWING A FIRST INITIAL MABTHERA I.V. TREATMENT, IN PATIENTS WITH NON-HODGKINS LYMPHOMA IN A REAL-LIFE SETTING
Phase of Trial: Phase III
Latest Information Update: 16 Sep 2016
Price : $35 *
At a glance
- Drugs Rituximab (Primary) ; Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Roche
- 01 Sep 2016 Status changed from active, no longer recruiting to completed.
- 01 Jul 2016 Planned End Date changed from 1 May 2016 to 1 Aug 2016.
- 01 Jul 2016 Planned primary completion date changed from 1 May 2016 to 1 Aug 2016.